Recent efforts in drug discovery on vascular inflammation and consequent atherosclerosis

Expert Opin Drug Discov. 2021 Apr;16(4):411-427. doi: 10.1080/17460441.2021.1850688. Epub 2020 Dec 15.

Abstract

Introduction: Preservation of vascular endothelium integrity and maintenance of its full functionality are fundamental aspects in order to avoid both cardiovascular and non-cardiovascular diseases.Areas covered: Although a massive endothelial disruption is a rare condition, caused by acute and uncontrolled inflammatory responses (e.g. the cytokine storm induced by SARS-CoV-2 infection), more frequently the vascular tree is the first target of slowly progressive inflammatory processes which affect the integrity of endothelium and its 'barrier' function, supporting the onset of atherosclerotic plaque and spreading inflammation. This endothelial dysfunction leads to decrease NO biosynthesis, impaired regulation of vascular tone, and increased platelet aggregation. Such chronic subclinic inflammation leads to macrophage infiltration in atherosclerotic lesions. Therefore, many efforts should be addressed to find useful approaches to preserve vascular endothelium from inflammation. In this review, the authors have evaluated the most recent strategies to counteract this pathological condition.Expert opinion: The therapeutic and nutraceutical approaches represent useful tools to treat or prevent different phases of vascular inflammation. In particular, the pharmacological approach should be used in advanced phases characterized by clinical signs of vascular disease, whilst the nutraceutical approach may represent a promising preventive strategy to preserve the integrity of the endothelial tissue.

Keywords: Atherosclerosis; SARS-CoV-2; endothelial dysfunction; nutraceutical approach; therapeutic strategies; vascular inflammation.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / etiology*
  • COVID-19 / complications*
  • Cytokine Release Syndrome / etiology*
  • Humans
  • Inflammation / etiology*
  • SARS-CoV-2*